2002
Prevention of Human Immunodeficiency Virus—Related Opportunistic Infections in France: A Cost-Effectiveness Analysis
Yazdanpanah Y, Goldie S, Paltiel A, Losina E, Coudeville L, Weinstein M, Gerard Y, Kimmel A, Zhang H, Salamon R, Mouton Y, Freedberg K. Prevention of Human Immunodeficiency Virus—Related Opportunistic Infections in France: A Cost-Effectiveness Analysis. Clinical Infectious Diseases 2002, 36: 86-96. PMID: 12491207, DOI: 10.1086/344902.Peer-Reviewed Original ResearchConceptsCost-effectiveness ratioTMP-SMZAntiretroviral therapyHIV diseaseOpportunistic infectionsHuman immunodeficiency virus (HIV) diseaseMycobacterium avium complex bacteremiaIncremental cost-effectiveness ratioPerson lifetime costsActive antiretroviral therapyEra of HAARTPneumocystis carinii pneumoniaHuman immunodeficiency virusQuality-adjusted life expectancyCost-effectiveness analysisOral ganciclovirCytomegalovirus infectionToxoplasmic encephalitisCarinii pneumoniaImmunodeficiency virusTherapeutic optionsClinical impactFrench patientsProphylaxisInfection
1998
The Cost-effectiveness of Preventing AIDS-Related Opportunistic Infections
Freedberg KA, Scharfstein JA, Seage GR, Losina E, Weinstein MC, Craven DE, Paltiel AD. The Cost-effectiveness of Preventing AIDS-Related Opportunistic Infections. JAMA 1998, 279: 130-136. PMID: 9440663, DOI: 10.1001/jama.279.2.130.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeAIDS-Related Opportunistic InfectionsAnti-Infective AgentsCD4 Lymphocyte CountChemopreventionCost-Benefit AnalysisCytomegalovirus InfectionsData CollectionHealth Care CostsHumansLife ExpectancyMarkov ChainsModels, TheoreticalMycobacterium avium-intracellulare InfectionMycosesPneumonia, PneumocystisQuality-Adjusted Life YearsRisk FactorsToxoplasmosisUnited StatesConceptsPneumocystis carinii pneumoniaCD4 cell countQuality-adjusted life expectancyOpportunistic infectionsCell countLife expectancyAdvanced human immunodeficiency virus diseaseAverage total lifetime costsHuman immunodeficiency virus (HIV) diseaseMycobacterium avium complex infectionMulticenter AIDS Cohort StudyIncremental cost-effectiveness ratioHIV patient careCost of prophylaxisCost-effective prophylaxisDirect medical costsAIDS Cohort StudyLifetime direct medical costsLong-term survivalCost-effectiveness ratioServices Utilization SurveyMarkov simulation modelTotal lifetime costsCytomegalovirus diseasePreventing AIDS